IPP Bureau
Kesin Pharma announces FDA approval and availability of Likmez oral suspension
By IPP Bureau - November 15, 2023
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
By IPP Bureau - November 15, 2023
Phase 3 data expected in the second half of 2024
Wockhardt Q2 FY24 consolidated loss lowers at Rs. 77 Cr
By IPP Bureau - November 15, 2023
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr
By IPP Bureau - November 15, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Solara Active Pharma Sciences posts consolidated Q2 FY2024 loss at Rs. 17.16 Cr
By IPP Bureau - November 15, 2023
Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023
Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’
By IPP Bureau - November 14, 2023
Yesafili, received marketing authorization approval from the European Commission for the European Union
AstraZeneca to leverage its capabilities to boost US renewable natural gas productivity
By IPP Bureau - November 14, 2023
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
BioPhy launches AI platform to accelerate the drug development market
By IPP Bureau - November 14, 2023
The company has raised US$4.5 million in funding for its AI operating system
Bayer and Recursion focus research collaboration on Oncology
By IPP Bureau - November 14, 2023
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Narayana Hrudayalaya Q2 FY PAT up at Rs. 226.58 Cr
By IPP Bureau - November 14, 2023
Narayana Hrudayalaya has reported total income of Rs. 1323.64 crores during the period ended September 30, 2023
Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr
By IPP Bureau - November 13, 2023
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Vaishali Pharma posts Q2 FY24 PAT at Rs. 1.70 Cr
By IPP Bureau - November 13, 2023
he company posted total income during Q2 FY24 at Rs. 12.86 crore
Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr
By IPP Bureau - November 13, 2023
European operations' revenue grew 58.4% to Rs 599.7 crore
Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr
By IPP Bureau - November 13, 2023
US business grew by +12.8% YoY
Sun Pharma joins hands with WOTR to create water harvesting capacity in Maharashtra
By IPP Bureau - November 13, 2023
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
